Evrys Bio is a Doylestown, Pennsylvania-based pharmaceutical company providing health care solutions to defend against viruses. Evrys Bio was founded on breakthrough discoveries from Princeton University.
Evrys Bio antivirals engage the cellular intrinsic immunity of the patient to fight viral infections. The company's vision is to develop safe antivirals that address the problem of acquired drug-resistance and provide unique broad-spectrum treatment options.
Evrys Bio products address the infectious disease condition, as opposed to targeting a specific virus-type, the practice of medicine will be transformed. Its highly-innovative products are early-stage and making progress in addressing real clinical challenges and unmet medical need.
Evrys Bio’s broad-spectrum antivirals are based on the discovery that certain human proteins, called sirtuins, normally defend the human (host) cell from being invaded by many different virus-types.Evrys Bio products will have the potential to transform the practice of medicine by offering treatment options that target a broad-spectrum of viral infections responsible for an entire infectious disease condition, such as respiratory infections.
By modulating sirtuin activity, Evrys Bio drugs restore metabolism that favors the host cell and enhances host defense-mechanisms while eliminating productive conditions for virus propagation.